---
title: "Avalyn Pharma names former FDA leader Robert J. Meyer to board"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299228479.md"
description: "Avalyn Pharma has appointed Robert J. Meyer to its board of directors. Meyer is a pulmonary physician with extensive experience, including recent roles at Greenleaf Health and previous senior positions at the FDA and Merck Research Laboratories."
datetime: "2026-09-16T20:01:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299228479.md)
  - [en](https://longbridge.com/en/news/299228479.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299228479.md)
generator: "portal-rs"
---

# Avalyn Pharma names former FDA leader Robert J. Meyer to board

-   Avalyn Pharma appointed Robert J. Meyer to its board of directors. \* Meyer is a pulmonary physician. He most recently served as principal of Drug and Biologics Products at Greenleaf Health. \* He previously held senior FDA roles, including Director of the Office of Drug Evaluation II, later serving as a vice president at Merck Research Laboratories. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalyn Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609161601PRIMZONEFULLFEED9828346) on September 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [AVLN.US](https://longbridge.com/en/quote/AVLN.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

- [Avalyn Pharma Director Robert J. Meyer files initial beneficial ownership statement](https://longbridge.com/en/news/299360082.md)
- [Avalyn Pharma reports Phase 1 data for inhaled nintedanib AP02 showing higher lung exposure, lower systemic levels](https://longbridge.com/en/news/299663715.md)
- [Microsoft's blazing stock comeback isn't even close to being over, analyst says](https://longbridge.com/en/news/300955443.md)
- [Michael Burry Raises Red Flag on Oracle’s $664B Backlog and AI Spending: ‘The Customer Is Now the Lender’](https://longbridge.com/en/news/300913488.md)
- [Tesla Stock Forecast: Q3 Delivery Beat Shifts Focus to Margins and AI](https://longbridge.com/en/news/300929376.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**